Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Lemos

Orthopaedic Surgery Saint Clair Shores, MI Medical Doctor

NPI 1740232792 CMS profile 214658

24715 Little Mack Ave Ste 100, Saint Clair Shores, MI 48080

Open in the dashboard

General payments

$5,357

30 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephen Lemos of Saint Clair Shores, MI is reported in the CMS Open Payments database as having received $5,357 across 30 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,082 8
2024 General $1,018 5
2023 General $140 2
2022 General $1,396 5
2021 General $274 4
2020 General $557 1
2019 General $889 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Lemos
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Stephen Lemos were reported at $1,082. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Stephen Lemos Orthopaedic Surgery median Middle half National median
2019 $889 $644 $140–$2,844 $163
2020 $557 $312 $75–$1,860 $114
2021 $274 $520 $117–$2,495 $132
2022 $1,396 $598 $128–$2,731 $149
2023 $140 $461 $128–$2,264 $160
2024 $1,018 $497 $134–$2,475 $164
2025 $1,082 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pinnacle, Inc $2,292 3 payments
  2. Encore Medical, LP $1,057 7 payments
  3. Linvatec Corporation $550 3 payments
  4. Djo, LLC $468 6 payments
  5. FX Shoulder USA, Inc $379 1 payment
  6. Stryker Corporation $137 2 payments
  7. DePuy Synthes Sales Inc. $126 1 payment
  8. Smith+Nephew, Inc. $115 2 payments
  9. Aesculap Biologics, LLC $109 1 payment
  10. Zimmer Biomet Holdings, Inc. $59 1 payment
  11. Other $64 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $2,292 3 payments
  2. Food and Beverage $1,767 22 payments
  3. Travel and Lodging $1,297 5 payments
Products named General payments · program years 2019–2025
  1. DJO SURGICAL $935 5 payments
  2. BIOBRACE 23MM $550 3 payments
  3. LIVATEC KNEE PRESERVATION SYSTEM $151 1 payment
  4. TRIATHLON $137 2 payments
  5. MAKO $137 2 payments
  6. NA $126 1 payment
  7. AIRCAST Bracing & Supports $119 1 payment
  8. PROCARE Bracing & Supports $119 1 payment
  9. PROCARE $118 2 payments
  10. NOVOCART 3D $109 1 payment
  11. Other $408 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

445

Median for Sports Medicine: 144

Drug cost

$3,635

Median for Sports Medicine: $1,027

Branded share of claims

13.7%

Median for Sports Medicine: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Etodolac Generic 78 $1,501
Cephalexin Generic 48 $501
Methylprednisolone Generic 83 $484
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 61 $380
Ondansetron Hcl Generic 49 $288
Trazodone Hcl Generic 75 $193
Dexamethasone Sodium Phosphate Generic 21 $154
Mupirocin Generic 14 $101
Tramadol Hcl Generic 16 $32

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$99,997

Of which drugs: $8,962

Medicare patients

140

Average age 73

Services billed

1,949

73 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Diabetes 33%
Ischemic heart disease 29%
Chronic kidney disease 24%
Atrial fibrillation 19%
Depression 19%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 22 152 $8,728
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 58 112 $87

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

30 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record